Posted by Michael Wonder on 19 Feb 2024
Health Canada approves Remsima SC for the treatment of inflammatory bowel disease
18 February 2024 - The approval is based on results from the LIBERTY studies demonstrating superior efficacy and comparable safety profiles of Remsima SC over placebo in patients with IBD.
Celltrion Healthcare Canada today announced that Health Canada has approved Remsima SC for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn’s disease.
